Search

… Immunotherapy Expert Dr. Pawel Kalinski Joins Roswell Park Comprehensive Cancer Center … dendritic cell program and tumor microenvironment Dr. Kalinski is a distinguished MD/PhD researcher in field of … - 08:00 04/27/2017 - 12:00 BUFFALO, N.Y. — Pawel Kalinski, MD, PhD, has joined Roswell Park Comprehensive …

… Roswell Park’s Dr. Pawel Kalinski to Lead $14.5M NCI-Funded Immunotherapy Effort … 03/31/2020 - 12:00 BUFFALO, N.Y. — A team led by Pawel Kalinski, MD, PhD, of Roswell Park Comprehensive Cancer … of the most commonly prescribed immunotherapies,” says Dr. Kalinski, who is Vice Chair for Translational Research, the …

… from a U.S. Department of Defense (DoD) grant to Pawel Kalinski, MD, PhD, Vice Chair for Translational Research and … A new dendritic-cell treatment vaccine developed by Dr. Kalinski and colleagues in collaboration with Brian … using a combination proposed and validated by Dr. Kalinski as an optimized adjuvant for dendritic-cell …

… led the study under the scientific leadership of Pawel Kalinski, MD, PhD, senior author of the paper, Chair of … Cancer Institute and U.S. Department of Defense, Dr. Kalinski directed earlier preclinical studies demonstrating … an easy-to-apply, short-term systemic treatment,” says Dr. Kalinski. CKM also may hold promise for treating other types …

… Emergent Strategies session. Dr. Kunle Odunsi Dr. Pawel Kalinski Kunle Odunsi, MD, FRCOG, FACOG, Deputy Director, … ovarian cancer during Immunotherapy Bridge 2020, and Pawel Kalinski, MD, PhD, Vice Chair for Translational Research, … Strategies session.   Dr. Kunle Odunsi   Dr. Pawel Kalinski Kunle Odunsi, MD, FRCOG, FACOG, Deputy Director, …

… Executive Director of the Center for Immunotherapy; Pawel Kalinski, MD, PhD, Vice Chair for Translational Research and … Executive Director of the Center for Immunotherapy; Pawel Kalinski, MD, PhD, Vice Chair for Translational Research and …

… development at Roswell Park under the leadership of Pawel Kalinski, MD, PhD, involving modulation of key proteins known … to immunotherapy and other forms of cancer treatment. Dr. Kalinski, Chair of the Department of Immunology and Chief of … development at Roswell Park under the leadership of Pawel Kalinski, MD, PhD, involving modulation of key proteins known …

… received $420,500 toward the clinical study led by Pawel Kalinski, MD, PhD, and Brahm Segal, MD, of a two-drug … immunotherapy combination as treatment for COVID-19. Dr. Kalinski has led pioneering studies proposing that … received $420,500 toward the clinical study led by Pawel Kalinski, MD, PhD, and Brahm Segal, MD, of a two-drug …